LONDON (dpa-AFX) - British drug major GSK plc (GSK, GSK.L) announced Tuesday that it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager or TCE for multiple my...
GSK To Buy T Cell-engager For Multiple Myeloma From Chimagen Biosciences For Up To $750 Mln
Source: Finanznachrichten.de
Read Full Story →